

FORM PTO-1449 (modified)

ATTY DOCKET NO.
22920.0003SERIAL NO.
09/671,283INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date submitted: 17 January 2001

APPLICANT:
John A. GIORDANO et al.FILING DATE
27 September 2000GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
MB	AA	4,357,343	11/1982	Madsen et al.			June 6, 1981
	AB	5,093,143	3/1992	Behr et al.			January 18, 1991
	AC	5,108,767	4/1992	Mulchandani et al.			June 10, 1991
	AD	5,728,678	3/1998	Trimbo et al.			June 6, 1995
MB	AE	4,957,938	9/1990	Anderson et al.			June 21, 1989

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

MB	AF	NEPHROLOGY DIALYSIS TRANSPLANTATION (1998) 13 [Suppl 2]: 23-27					
	AG	Holben and Smith, 99(7) JOURNAL OF THE AMERICAN DIETETIC ASSOC. 836-843 (1999)					
	AH	Pönkä and Kuhlback, 213 ACTA MED. SCAND. 305-307 (1983)					
	AI	Anderson et al., 54 AM. J. CLIN. NUTR. 909-916 (1991)					
	AJ	British Medical Journal, HYPERVITAMINOSIS A ACCOMPANYING ADVANCED CHRONIC RENAL FAILURE (1975)					
	AK	Burton and Ingold, VITAMIN E AS AN IN VITRO AND IN VIVO ANTIOXIDANT 7-22					
	AL	Burk, 3 BIOLOGICAL ACTIVITY OF SELENIUM 53-70 (1983)					
	AM	Rolton et al., 6 NEPHROL. DIALYSIS TRANSPLANT 440-443 (1991)					
	AN	Ono, 26(5) CLINICAL NEPHROLOGY 239-243 (1986)					
	AO	Hultberg et al., 40(4) CLINICAL NEPHROLOGY 230-234 (1993)					
	AP	Ono, 40 VITAMIN E SUPPLEMENTATION IN ANEMIA 440-445 (1985)					
	AQ	Parfrey, 23 ADVANCES IN NEPHROLOGY 311-330 (1994)					
	AR	Lacour, 127 CLINICA CHIMICA ACTA 205-215 (1983)					
	AS	Allman et al., 150 THE MEDICAL JOURNAL OF AUSTRALIA 130-133					
	AT	Vincent, THE BIOCHEMISTRY OF CHROMIUM 715-718					
MB	AU	Fraker et al., LINK BETWEEN IMMUNE STATUS AND ZINC STATUS 1399S-1406S					

EXAMINER

DATE CONSIDERED

03/05/02

*EXAMINER: Initial if reference considered. whether or not citation is in conformance with MPEP 609: draw line through



Sheet 2 of 2

FORM PTO-1449 (modified)

ATTY DOCKET NO.
22920.0003

SERIAL NO.
09/671,285

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date submitted: 17 January 2001

APPLICANT:
John A. DIORDANO et al.

FILING DATE
27 September 2000

GROUP
1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

RECEIVED

JAN 19 2001

TECH CENTER 1600/2000

M/S	BA	Fukagawa et al., 21 MINERAL ELECTROLYTE METAB. 97-100 (1995)
	BB	Islam et al., 150 ASTHEROSCLEROSIS 217-224 (2000)
	BC	Hoogeveen, HYPERHOMOCYSTEINEMIA, TYPE 2 DIABETES, AND MORTALITY 1506-1511
	BD	Moustapha, HOMOCYSTEINE AND RENAL FAILURE 138-141
	BE	Robinson et al., 94(11) CIRCULATION 2743-2748 (1996)
	BF	Jungers et al., 14 NEPHROL. DIALYSIS TRANSPLANT 2903-2906 (1999)
	BG	Arnadottir et al., 15 NEPHROL. DIALYSIS TRANSPLANT 524-528 (2000)
	BH	Janssen et al., 22 MINER ELECTROLYTE METAB. 110-114 (1996)
	BI	Bostom et al., 49 KIDNEY INTERNATIONAL 147-152 (1996)
	BJ	Oishi et al., 15 NEPHROL. DIALYSIS TRANSPLANT 851-855 (2000)
	BK	Perna et al., 25 MINERAL AND ELECTROLYTE METABOLISM 95-99 (1999)
	BL	Bögye et al., 84 NEPHRON 119-123 (2000)
M/S	BM	Kornatowska et al., 13 NEPHROLOGY DIALYSIS TRANSPLANTATION 2829-2832 (1998)

EXAMINER

DATE CONSIDERED

03/05/00

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*